Ravulizumab is a type of monoclonal antibody used to treat adults with Paroxysmal Nocturnal Hemoglobinuria (PNH).
PNH is a rare life-threatening disease of the blood in which there is destruction of red blood cells by the complement (part of the body's innate immune system).

Ravulizumab is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria 

It should not be used in patients with unresolved meningitis

Ravulizumab is available as an Injection.
Dose is 300 mg/30mL (10 mg/mL).

If a Ravulizumab infusion is missed, call your doctor right away.

Ravulizumab is given as an intravenous infusion.
It's dose is based on body weight.

•Life-threatening meningococcal infections could occur in patients treated with Ravulizumab. They should be addressed immediately.
• Follow the recommendations of the current Advisory Committee on Immunization Practices (ACIP) for meningococcal vaccination among patients with complement deficiencies two weeks before usage of ravulizumab.
• Ravulizumab is available under Risk Evaluation and Mitigation Strategy (REMS). Healthcare professionals who prescribe ravulizumab must enroll in the ravulizumab REMS.
• Caution is needed while prescribing ravulizumab to patients with systemic infections.
• After stopping the treatment, monitor for signs and symptoms of hemolysis for 16 weeks.
These Signs include decrease in haemoglobin, or re-appearance of fatigue, hemoglobinuria, abdominal pain, breathing difficulties, thrombosis (blood clotting), dysphagia (painful swallowing), or erectile dysfunction.

Commonest side effects of Ravulizumab are upper respiratory infection and headache.
Other side effects:
•  Gastrointestinal: Diarrhea, Nausea, Abdominal pain
•  Nervous system: Dizziness
•  Musculoskeletal: Pain in extremities(feet, legs, fingers), arthralgia(joint pain)
•  General disorders: Pyrexia(fever)
•  Infusion-related: Low back pain, drop in blood pressure and infusion-related pain. Interrupt the infusion and give supportive measures in this case.

Tell your physician if you are pregnant or planning to become pregnant or if you are breastfeeding or planning to breastfeed. You should not breast-feed during the treatment and for 8 months after the last dose of ravulizumab.

Ravulizumab vials are refrigerated at 2°C – 8°C. Do not freeze.
It should be protected from light.